Three-Drug combo tested to keep blood cancer at bay after transplant
NCT ID NCT02659293
Summary
This study compares two maintenance treatments for multiple myeloma patients who have received a stem cell transplant. Researchers want to see if a three-drug combination (carfilzomib, lenalidomide, dexamethasone) works better than lenalidomide alone at preventing the cancer from returning. The trial involves 180 participants who will be randomly assigned to one of the two treatment groups and followed to see how long they remain cancer-free.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Polish Myeloma Consortium
Poznan, Poland
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Wayne State University - Karmanos Cacner Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.